[{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2024-07-02T16:34:26.619Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression • PD-L1 amplification","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression • PD-L1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-06-13"},{"id":"6c31d924-416a-4fac-90f3-4e9e04970c2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708470","created_at":"2021-01-19T20:51:59.772Z","updated_at":"2024-07-02T16:34:36.870Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers","source_id_and_acronym":"NCT04708470","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jingzhuda (entinostat) • bintrafusp alfa (M7824) • PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 10/05/2021","start_date":" 10/05/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-10"},{"id":"f1ad940d-0158-42e2-8647-51b32c5f7ee6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05565417","created_at":"2022-10-04T15:57:50.214Z","updated_at":"2024-07-02T16:35:06.273Z","phase":"Phase 1/2","brief_title":"Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT05565417","lead_sponsor":"Immunitas Therapeutics","biomarkers":" KRAS • BRAF • ALK • PIK3CA • MET • MSI","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • HR positive • MSI-H/dMMR • HER-2 overexpression • PIK3CA mutation","tags":["KRAS • BRAF • ALK • PIK3CA • MET • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • HR positive • MSI-H/dMMR • HER-2 overexpression • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fruzaqla (fruquintinib) • IMT-009"],"overall_status":"Recruiting","enrollment":" Enrollment 151","initiation":"Initiation: 11/28/2022","start_date":" 11/28/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-05-03"},{"id":"9b174ee5-8688-4ac7-9766-32255efdc8a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04729322","created_at":"2021-01-28T12:53:13.830Z","updated_at":"2024-07-02T16:35:06.392Z","phase":"Phase 2","brief_title":"Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders","source_id_and_acronym":"NCT04729322","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MSI • MLH1 • MSH6 • MSH2 • CEACAM5","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • MLH1 • MSH6 • MSH2 • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/22/2021","start_date":" 02/22/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-02"},{"id":"46d378ac-a32a-49b5-8f63-3c539b277a13","acronym":"QPCS","url":"https://clinicaltrials.gov/study/NCT04104230","created_at":"2021-01-18T20:04:23.369Z","updated_at":"2024-07-02T16:35:09.050Z","phase":"","brief_title":"Quebec Pancreas Cancer Study","source_id_and_acronym":"NCT04104230 - QPCS","lead_sponsor":"George Zogopoulos","biomarkers":" BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1","pipe":" | ","alterations":" ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 03/12/2012","start_date":" 03/12/2012","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-04-17"},{"id":"f6e5063d-4d72-41b4-bb83-56a09d9eca4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05223036","created_at":"2022-02-05T18:29:25.061Z","updated_at":"2024-07-02T16:35:09.567Z","phase":"Phase 2","brief_title":"Testing Obeticholic Acid for Familial Adenomatous Polyposis","source_id_and_acronym":"NCT05223036","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" APC","pipe":" | ","alterations":" APC mutation","tags":["APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 01/19/2023","start_date":" 01/19/2023","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 02/21/2026","study_completion_date":" 02/21/2026","last_update_posted":"2024-04-16"},{"id":"31d7ee1a-3f75-40a4-8d61-0c58c2bd4ffc","acronym":"NCI-2018-01399","url":"https://clinicaltrials.gov/study/NCT03108131","created_at":"2021-01-18T15:18:44.409Z","updated_at":"2024-07-02T16:35:11.100Z","phase":"Phase 2","brief_title":"Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors","source_id_and_acronym":"NCT03108131 - NCI-2018-01399","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cotellic (cobimetinib)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 04/07/2017","start_date":" 04/07/2017","primary_txt":" Primary completion: 04/02/2024","primary_completion_date":" 04/02/2024","study_txt":" Completion: 04/02/2024","study_completion_date":" 04/02/2024","last_update_posted":"2024-04-05"},{"id":"6546b0c5-710f-4af5-b959-a7792033251c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02381561","created_at":"2021-01-29T07:07:48.027Z","updated_at":"2024-07-02T16:35:15.997Z","phase":"Phase 1","brief_title":"Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy","source_id_and_acronym":"NCT02381561","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ropidoxuridine (IPdR)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 11/08/2018","primary_completion_date":" 11/08/2018","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2024-03-07"},{"id":"a507c28a-87c0-4461-a856-ff35aefcb93f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01815749","created_at":"2021-01-18T08:03:43.924Z","updated_at":"2024-07-02T16:35:24.544Z","phase":"Phase 1","brief_title":"Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT01815749","lead_sponsor":"City of Hope Medical Center","biomarkers":" EGFR • CD34","pipe":"","alterations":" ","tags":["EGFR • CD34"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/08/2013","start_date":" 10/08/2013","primary_txt":" Primary completion: 01/09/2018","primary_completion_date":" 01/09/2018","study_txt":" Completion: 09/27/2024","study_completion_date":" 09/27/2024","last_update_posted":"2024-01-04"},{"id":"90de6fd3-b3e6-4a87-a805-ec66b3a485de","acronym":"ZEBRA","url":"https://clinicaltrials.gov/study/NCT02949219","created_at":"2021-01-18T14:29:04.610Z","updated_at":"2024-07-02T16:35:25.042Z","phase":"Phase 2","brief_title":"Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02949219 - ZEBRA","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" PD-L1 • MSI","pipe":"","alterations":" ","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 03/24/2017","start_date":" 03/24/2017","primary_txt":" Primary completion: 01/31/2019","primary_completion_date":" 01/31/2019","study_txt":" Completion: 03/31/2024","study_completion_date":" 03/31/2024","last_update_posted":"2023-12-28"},{"id":"37a98dbf-8c6e-4480-bbe8-7278b9a8df75","acronym":"ARM-GI","url":"https://clinicaltrials.gov/study/NCT04221893","created_at":"2021-01-18T20:32:57.712Z","updated_at":"2024-07-02T16:35:28.890Z","phase":"","brief_title":"Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers","source_id_and_acronym":"NCT04221893 - ARM-GI","lead_sponsor":"University of California, San Francisco","biomarkers":" MSI • PD-1","pipe":"","alterations":" ","tags":["MSI • PD-1"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 08/07/2020","start_date":" 08/07/2020","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2023-11-17"},{"id":"022a29da-b197-4827-a622-2e8a2fce79e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04491955","created_at":"2021-01-18T21:34:47.909Z","updated_at":"2024-07-02T16:35:29.342Z","phase":"Phase 2","brief_title":"Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers","source_id_and_acronym":"NCT04491955","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CEACAM5 • CD4","pipe":"","alterations":" ","tags":["CEACAM5 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • Anktiva (nogapendekin alfa inbakicept-pmln) • PDS01ADC • Panvac-VF (falimarev/inalimarev)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 09/22/2020","start_date":" 09/22/2020","primary_txt":" Primary completion: 10/25/2022","primary_completion_date":" 10/25/2022","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2023-11-14"},{"id":"2f6706b3-4373-4123-bd41-4a6388aa2fbf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04566393","created_at":"2021-01-18T21:48:48.647Z","updated_at":"2024-07-02T16:35:39.652Z","phase":"","brief_title":"Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies","source_id_and_acronym":"NCT04566393","lead_sponsor":"xCures","biomarkers":" BRAF • NRAS • HRAS • MAPK1","pipe":" | ","alterations":" BRAF mutation • ER mutation • HRAS mutation","tags":["BRAF • NRAS • HRAS • MAPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • ER mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ulixertinib (BVD-523)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2023-08-21"},{"id":"a86eae23-5fcb-4a8b-a5e6-a0ef3b33f450","acronym":"","url":"https://clinicaltrials.gov/study/NCT02213913","created_at":"2021-01-18T10:22:23.451Z","updated_at":"2024-07-02T16:35:49.349Z","phase":"Phase 1/2","brief_title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","source_id_and_acronym":"NCT02213913","lead_sponsor":"University of Chicago","biomarkers":" MYC • BCL2 • CD20 • BCL6 • IRF4 • MME","pipe":" | ","alterations":" BCL2 positive","tags":["MYC • BCL2 • CD20 • BCL6 • IRF4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • melphalan • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 07/29/2014","start_date":" 07/29/2014","primary_txt":" Primary completion: 07/29/2023","primary_completion_date":" 07/29/2023","study_txt":" Completion: 07/29/2023","study_completion_date":" 07/29/2023","last_update_posted":"2023-04-28"},{"id":"a5987937-3183-4133-b867-a1d2653afe5c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05194995","created_at":"2022-01-18T12:54:15.051Z","updated_at":"2024-07-02T16:35:53.559Z","phase":"Phase 1/2","brief_title":"JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation","source_id_and_acronym":"NCT05194995","lead_sponsor":"Jacobio Pharmaceuticals Co., Ltd.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • glecirasib (JAB-21822)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 02/17/2022","start_date":" 02/17/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2023-03-10"},{"id":"8e80a1b3-de6a-423e-b0c9-1f511f4dd8f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05704010","created_at":"2023-01-30T18:59:51.794Z","updated_at":"2024-07-02T16:35:56.820Z","phase":"","brief_title":"Videocapsule Endoscopy in Lynch Syndrome","source_id_and_acronym":"NCT05704010","lead_sponsor":"San Raffaele University","biomarkers":" MLH1 • MSH6 • MSH2 • EPCAM","pipe":"","alterations":" ","tags":["MLH1 • MSH6 • MSH2 • EPCAM"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/01/2018","start_date":" 11/01/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-01-30"},{"id":"7913bd88-7337-489f-b117-4bee3edb31e7","acronym":"NutriGIT","url":"https://clinicaltrials.gov/study/NCT04476082","created_at":"2021-01-18T21:30:01.581Z","updated_at":"2024-07-02T16:35:57.142Z","phase":"","brief_title":"Nutrition in Gastrointestinal Tumors","source_id_and_acronym":"NCT04476082 - NutriGIT","lead_sponsor":"University Medicine Greifswald","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"],"overall_status":"Completed","enrollment":" Enrollment 66","initiation":"Initiation: 06/25/2020","start_date":" 06/25/2020","primary_txt":" Primary completion: 12/06/2022","primary_completion_date":" 12/06/2022","study_txt":" Completion: 12/06/2022","study_completion_date":" 12/06/2022","last_update_posted":"2023-01-24"},{"id":"9a28d489-9909-417b-b32a-2274c2c36b22","acronym":"PRO-YOU","url":"https://clinicaltrials.gov/study/NCT02489422","created_at":"2021-01-18T11:59:59.431Z","updated_at":"2024-07-02T16:36:02.462Z","phase":"","brief_title":"Programs To Support You During Chemotherapy","source_id_and_acronym":"NCT02489422 - PRO-YOU","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" IL6 • TNFA • TNFRSF1A","pipe":"","alterations":" ","tags":["IL6 • TNFA • TNFRSF1A"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2022-10-14"},{"id":"ea11b224-f9b4-42a8-b2f1-ec4f488885da","acronym":"PORTAL","url":"https://clinicaltrials.gov/study/NCT04400357","created_at":"2021-01-18T21:13:46.986Z","updated_at":"2024-07-02T16:36:11.094Z","phase":"Phase 3","brief_title":"Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors","source_id_and_acronym":"NCT04400357 - PORTAL","lead_sponsor":"Ruijin Hospital","biomarkers":" IL6 • CRP","pipe":"","alterations":" ","tags":["IL6 • CRP"],"overall_status":"Recruiting","enrollment":" Enrollment 244","initiation":"Initiation: 06/15/2020","start_date":" 06/15/2020","primary_txt":" Primary completion: 10/07/2022","primary_completion_date":" 10/07/2022","study_txt":" Completion: 11/30/2022","study_completion_date":" 11/30/2022","last_update_posted":"2022-05-03"},{"id":"1ae2a3a3-6728-4257-87af-f63fd6f956aa","acronym":"NETTER-1","url":"https://clinicaltrials.gov/study/NCT01578239","created_at":"2021-01-18T06:42:58.061Z","updated_at":"2024-07-02T16:36:14.196Z","phase":"Phase 3","brief_title":"A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours","source_id_and_acronym":"NCT01578239 - NETTER-1","lead_sponsor":"Advanced Accelerator Applications","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • octreotide acetate"],"overall_status":"Completed","enrollment":" Enrollment 231","initiation":"Initiation: 09/06/2012","start_date":" 09/06/2012","primary_txt":" Primary completion: 07/31/2015","primary_completion_date":" 07/31/2015","study_txt":" Completion: 01/18/2021","study_completion_date":" 01/18/2021","last_update_posted":"2022-04-04"},{"id":"8c98a344-0d2c-4fa6-bb06-872f8a0085b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01202409","created_at":"2021-01-18T04:49:03.575Z","updated_at":"2024-07-02T16:36:49.698Z","phase":"Phase 2","brief_title":"CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater","source_id_and_acronym":"NCT01202409","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 11/02/2010","start_date":" 11/02/2010","primary_txt":" Primary completion: 07/03/2018","primary_completion_date":" 07/03/2018","study_txt":" Completion: 07/03/2018","study_completion_date":" 07/03/2018","last_update_posted":"2020-02-21"},{"id":"72775712-a31f-4bce-b25f-5e8894062042","acronym":"","url":"https://clinicaltrials.gov/study/NCT03346980","created_at":"2021-01-22T19:52:19.736Z","updated_at":"2024-07-02T16:36:50.062Z","phase":"","brief_title":"Endoscopic Evaluation of Duodenal Polyposis in Patients With Familial Adenomatous Polyposis (FAP)","source_id_and_acronym":"NCT03346980","lead_sponsor":"Copenhagen University Hospital, Hvidovre","biomarkers":" APC","pipe":" | ","alterations":" APC mutation","tags":["APC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 12/01/2017","start_date":" 12/01/2017","primary_txt":" Primary completion: 01/23/2020","primary_completion_date":" 01/23/2020","study_txt":" Completion: 01/23/2020","study_completion_date":" 01/23/2020","last_update_posted":"2020-02-13"},{"id":"f5e017b5-0807-4ad2-82cc-1eac54c0227b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00089011","created_at":"2021-01-18T00:15:55.458Z","updated_at":"2024-07-02T16:36:50.732Z","phase":"Phase 2","brief_title":"Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer","source_id_and_acronym":"NCT00089011","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 150","initiation":"Initiation: 04/01/2004","start_date":" 04/01/2004","primary_txt":" Primary completion: 03/01/2014","primary_completion_date":" 03/01/2014","study_txt":" Completion: 07/01/2018","study_completion_date":" 07/01/2018","last_update_posted":"2020-01-29"},{"id":"fa403d6d-951f-4be6-91dc-1d14f8ed43ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT01730586","created_at":"2021-01-18T07:34:11.774Z","updated_at":"2024-07-02T16:36:51.155Z","phase":"Phase 2","brief_title":"Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas","source_id_and_acronym":"NCT01730586","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • MLH1","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS • MLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 11/01/2012","start_date":" 11/01/2012","primary_txt":" Primary completion: 08/01/2016","primary_completion_date":" 08/01/2016","study_txt":" Completion: 08/01/2016","study_completion_date":" 08/01/2016","last_update_posted":"2020-01-18"}]